FDA Warns Novartis of Violations at Three Plants - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Warns Novartis of Violations at Three Plants

ePT--the Electronic Newsletter of Pharmaceutical Technology

In a Warning Letter, FDA cited “significant violations” of CGMP regulations, including several repeat observations, at three Novartis facilities. The violations included failure to prevent microbiological contamination of sterile drug products, failure to investigate out-of-specification batches, failure to clean and maintain equipment, and failure to ensure drugs’ identity, strength, quality, and purity.

FDA officials observed the violations during three inspections of Novartis’s Sandoz unit in Broomfield, Colorado; Wilson, North Carolina; and Boucherville, Canada. The inspections took place on three occasions from April to August 2011.

All three violations cited at the Boucherville facility were repeat observations from a July 2009 FDA inspection. In the Warning Letter, FDA noted that the firm had neglected to investigate batch failures or implement corrective actions. For example, Novartis failed to determine the cause of the crystallization of an injectable solution, according to the letter. “We are concerned that your firm lacks process understanding to consistently manufacture” the product, FDA wrote. “Your failure to implement appropriate corrective actions and prevent future recurrence is indicative of an ineffective quality system,” the agency added.

The Wilson and Broomfield plants failed to ensure that their products had the appropriate strength, quality, and purity. These observations were repeat violations from an August 2008 Warning Letter.

In addition, investigators observed that several pieces of equipment at the Broomfield facility “were still dirty after cleaning had been completed and verified by a supervisor,” according to the letter. Although the company claimed that the insufficient cleaning was an isolated instance, the letter noted that it was a repeated violation from the August 2008 Warning Letter. “We are concerned that your firm has been cited for inadequate cleaning during a number of previous inspections, and that you have promised corrective actions but our inspections continue to reveal problems in this area of CGMP,” said the letter.

See related Pharm Tech articles:

EC Probes J&J and Novartis (ePT)

Novartis Updates Long-Term Strategy (ePT)

Big Pharma's Manufacturing Blueprint for the Future (Pharm Tech)


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here